Peer-reviewed article
Assessing the Impact of Rotavirus Vaccination in Iranian Children Under Five: An Agent-Based Modelling Approach.
Amirhesam Moosazadeh, Babak Eshrati, Ebrahim Babaee ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This study used computer modelling to predict how introducing rotavirus vaccination (Rotasiil) into Iran's national immunization program would affect children under five. The model simulated disease transmission in both urban and rural settings, assuming 98% vaccine coverage and 55% effectiveness based on trial data. The results suggest vaccination would reduce rotavirus cases by about 27-34% and cut the number of days children are ill by similar amounts in both settings.
Key points
- Vaccination reduced urban incidence from 0.663 to 0.440 cases per child-year (33.6% reduction)
- Vaccination reduced rural incidence from 0.670 to 0.488 cases per child-year (27.2% reduction)
- Symptomatic disease days decreased by 33.7% in urban and 27.3% in rural settings
- Sensitivity analyses showed consistent 26-33% reductions across different incidence assumptions
- Vaccination resulted in lower epidemic peak intensity and more stable disease dynamics
Limitations
This is a modelling study based on simulated populations, not actual observed outcomes in real children. The predictions depend on achieving 98% coverage and 55% seroconversion rates, which may not occur in practice, and do not account for factors like vaccine cold-chain reliability or equity in access across regions.
Abstract
BACKGROUND AND AIMS: Rotavirus is a leading cause of severe diarrhoeal disease in young children worldwide. In 2024, Iran introduced the pentavalent oral vaccine Rotasiil® into its national immunization program. This study aimed to estimate its potential epidemiological impact using an agent-based modeling (ABM) approach. METHODS: An ABM was developed in NetLogo 6.4.0 to simulate rotavirus transmission among children under five in urban and rural settings. Agents represented individual children with attributes such as age, mobility, and susceptibility. Transmission occurred through contact within defined spatial grids, with higher probabilities assigned to rural settings to reflect poorer sanitation. Disease progression included incubation, symptomatic period, temporary immunity, and rare mortality. Two vaccination conditions (vaccinated vs. unvaccinated) were simulated, assuming 98% coverage and 55% seroconversion, consistent with Rotasiil-Liquid trial data. Population turnover and births were incorporated. Each condition was run 1,000 times over one simulated year, and incidence rates and symptomatic days per child-year were calculated. Sensitivity analyses tested low- and high-incidence assumptions. RESULTS: In urban settings, vaccination reduced incidence from 0.663 to 0.440 cases per child-year (- 33.6%) and disease days from 3.895 to 2.584 (- 33.7%; p < 0.001). In rural populations, incidence declined from 0.670 to 0.488 (- 27.2%) and disease days from 3.968 to 2.886 (- 27.3%; p < 0.001). Sensitivity analyses showed consistent reductions of 26%-33% across incidence levels. Epidemic curves demonstrated lower peak intensity and more stable dynamics with vaccination. CONCLUSION: Rotasiil is expected to substantially reduce rotavirus burden in Iran, lowering incidence, symptomatic days, and epidemic peak size. These results support the inclusion of rotavirus vaccination as a key child health intervention, though continued post-introduction surveillance remains essential.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Introduction of pentavalent oral rotavirus vaccine (Rotasiil) into national immunization program with assumed 98% coverage and 55% seroconversion
- Population
- Children under five in Iran, simulated in urban and rural settings
Key finding
Urban incidence reduced 33.6% (0.663 to 0.440 cases per child-year, p<0.001)